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Abstract 
 
This thesis focuses on understanding the biological functions of HOXA5 in 
mammary epithelial differentiation and breast cancer progression. Members of HOX 
cluster have long been associated with cellular differentiation. Nonetheless, how HOX 
genes drive differentiation in mammalian cells is poorly understood. The expression of 
HOXA5 is frequently deregulated in breast cancer, while higher HOXA5 expression 
predicts better relapse free survival in breast cancer patients. My research has 
demonstrated that depleting HOXA5, a key regulator during embryogenesis, increases 
cell plasticity and stemness in the human breast epithelial cell line, MCF10A. 
Comparison of MCF10A cells and HOXA5-depleted MCF10A cells by expression 
array analysis revealed HOXA5’s ability to regulate several traits of epithelial lineage, 
including E-cadherin and CD24. Analysis of the expression array by gene set 
enrichment analysis (GSEA) confirmed the negative correlation between epithelial traits 
and the transcriptome of HOXA5-depleted MCF10A cells. Using an inducible HOXA5-
knockdown system, we demonstrated how HOXA5 depletion restrained state transition 
from CD24
-
/CD44
+ 
to CD24
+
/CD44
+ 
cells upon treatment of retinal. The increase of 
expression of adhesions proteins was, however, impeded when HOXA5 was 
simultaneously repressed. Failure of state transition upon depletion of HOXA5 resulted 
in increased ability for mammosphere formation. Furthermore, depleting HOXA5 in 
MCF10A-KRAS transformed cells reduced CD24
+
/CD44
lo
 population and enhanced the 
iii 
 
self-renewal capacity of MCF10A-KRAS cells in culture. In Matrigel, these cells 
exhibited stellate and protrusive morphology which suggested the transition of the 
cancer cell to a more progenitor-like state. HOXA5-depleted MCF10-KRAS cells failed 
to develop pseudo-luminal architecture in orthotopically engrafted xenografts. Ectopic 
expression of HOXA5 in SUM149, on the other hand, resulted in an increased 
CD24
+
/CD44
-
 population and inhibition of mammosphere formation in culture and 
tumor initiation in vivo. Mechanistically, we showed that wild type HOXA5 induced 
luciferase activity regulated by the proximal promoter region of E-cadherin and CD24 
in 293T cells. We further confirmed the recruitment of HOXA5 to putative consensus 
HOXA5 binding site, TAAT, to these promoters by ChIP analysis. Collectively, these 
findings support a role for HOXA5 in cell differentiation by up-regulating epithelial 
traits and suppressing tumor aggressiveness in breast cancer. 
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1 Introduction 
 
HOX genes belong to the largest homeodomain containing superfamily whose 
members are primarily responsible for establishing cell fate in multicellular organism. 
Members of the HOX clusters were first identified during 1970-1980 in Drosophila 
through a series of experiments conducted by Edward B. Lewis, Christiane Nüsslein-
Volhard and Eric F. Wieschaus. Mutants of HOX genes transform the body patterning 
of Drosophila during embryogenesis, and hence they were given the name-homeotic 
genes (maintain homeosis). Unlike the other homeotic genes, HOX genes are clustered 
in proximity in the genome. There are four HOX (A-D) clusters in human genome, 
which are located at chromosome 2, 12, 7 and 17 respectively (Figure 1). It is generally 
believed that these clusters evolved from a common ancestor during evolution. It is also 
fascinating that the order of expression of the HOX genes follows the sequence of their 
Figure 1. HOX gene clusters  
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positions on the chromosome in the developing embryo. But the purpose for this 
collinearity and the mechanism of this regulation are still poorly understood. Retinoic 
acid is a potent differentiating factor which is known to control the collinear expression 
of HOX genes in teratoma cell line (Simeone et al 1990, Stornaiuolo et al 1990). The 
connection between retinoids and HOX genes suggests that the latter play an 
intermediary role in regulating differentiation in mammalian cells. However, the role of 
HOX genes in the differentiating cascades induced by retinoic acid remains poorly 
understood. 
Members of both HOX and retinoic acid receptor (RAR) families are known to 
be associated with cellular differentiation (Kondo et al 1992, Marshall et al 1996, Pratt 
et al 1993, Zwartkruis et al 1993). HOX genes are transcription factors that orchestrate 
body segmentation during embryogenesis (Alexander et al 2009, Dubrulle et al 2001) 
and perturbed HOX expression has been implicated in cancer (Shah and Sukumar 2010). 
The mammary gland is an organ that continues to go through multiple cycles of 
development during life. Moreover, persistent expression of several HOX members in 
adulthood suggests the necessity of their biological functions in maintaining tissue 
homeostasis and differentiation (Taylor et al 1997, Yan et al 2013). Hence, suppression 
of specific HOX genes in adulthood could be detrimental to normal mammary gland 
development.  
Sex comb reduced (Scr), the ortholog of HOXA5 in Drosophila, promotes  
normal development of the salivary gland (Haberman et al 2003, Henderson and 
Andrew 2000). Scr is primarily expressed in the primitive cells that form the salivary 
gland. However, Scr mRNA expression ceases as the glandular cells invaginate. In fact, 
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de novo salivary glands form at new body segments when Scr is ectopically expressed 
throughout the embryo. It is unclear how the spatial temporal expression Scr regulates 
the development of salivary gland in Drosophila. On the other hand, Hoxa5-/- mice 
display severe postnatal abnormalities. Mammary gland development is impaired in the 
surviving mutant mice, which is the result of the loss of Hoxa5 functions in the stromal 
compartment (Garin et al 2006). 
Among the HOX genes clusters, members of the HOXA cluster are frequently 
silenced through epigenetic regulation in different types of cancer (Novak et al 2006). 
Silencing of HOXA5 in breast cancer has been associated with promoter hyper-
methylation (Watson et al 2004). Investigations from our laboratory have reported loss 
of HOXA5 in breast cancer and its tumor suppressive function in promoting apoptosis 
in breast cancer in a p53-dependent and independent manner (Chen et al 2004, Raman 
et al 2000).  Given the strong influence of retinoic acid in the direct transcriptional 
activation of HOXA5 (Chen et al 2007) and mammary gland development (Chute et al 
2006), we sought to understand the function of HOXA5 in mammary epithelial cell 
differentiation and its tumor suppressive effects during breast cancer progression.  
The majority of apocrine glands including the mammary gland are composed 
primarily of epithelial cells. Epithelium is characterized by its tightly packed pattern, 
displaying anterior posterior polarity, by which they serve as a barrier between the 
outside environment and the body. The epithelial cells are attached to each other 
through cell-cell junctions. E-cadherin is the major component of adhesion junctions 
which link intracellular actin filaments via catenins. Another cell-cell junction called 
tight junctions consists of Occludin and Claudins; the complex anchors intracellular 
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cytoskeleton through ZO-1. Loss of junction proteins disrupts the polarity of epithelial 
cells and hence impairs their normal functions. Decrease in cell-cell junctions is a 
typical hallmark of cancer progression, promotes migration and is likely to promote 
local and distant metastasis (Jeanes et al 2008, Martin and Jiang 2009).  
It has been speculated that a population of cells within a tumor or cancer is 
capable of initiating tumor fomration independantly. These cells are self-renewal and 
are capable to 
generate more 
differented cells, 
resembling the 
characterics of 
normal stem cells.  
Research in the 
last twenty years 
has identified multiple markers common to both normal and breast cancer 
stem/progenitor cells. The most commonly used among them is the distribution on the 
cells of two cell surface markers, CD24
-/low
/CD44
+
 (Figure 2). The surface markers 
were discovered through xenograft assays using specific populations isolated from 
primary breast cancer (Al-Hajj et al 2003). It has been further shown in a number of 
studies that this subpopulation, which is characterized by high levels of expression of 
CD44 and low or undetectable levels of CD24, displays robust self-renewal and 
tumorigenic properties (Dontu et al 2003, Ponti et al 2005). Cells that display CD24-
/low
/CD44
+
 progenitor cell surface markers exhibit mesenchymal or basal cell properties 
Figure 2. Prospective 
identification of tumorigenic 
breast cancer cells.  
(Al-Hajj et al 2003)  
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(Mani et al 2008, May et al 2011, Radisky and LaBarge 2008), and are highly invasive 
and motile compared to their counterparts that express high levels of CD24 (Sheridan et 
al 2006), express low levels of the adhesion molecule, E-cadherin (Klopp et al 2010, 
Radisky and LaBarge 2008), and exhibit a cytokeratin profile resembling basal 
epithelium (Honeth et al 2008).  
Among known markers of differentiation, CD24 is glycosyl-phosphatidyl-
inositol linked cell surface molecule that has been implicated in lineage development of 
hematopoietic cells (Kay et al 1991).  CD24 expression is low in progenitor/basal cells 
(Petkova et al 2013, Sleeman et al 2006), but whether it has any biological functions in 
regulating cell differentiation and specification is as yet unknown. Also, little is known 
about transcriptional regulation of CD24. The second is retinoic acid, which is a 
signaling molecule that is produced in the stem cell niche and implicated in stem cell 
differentiation and induction of lineage progression in hematopoietic cells in vitro 
(Chute et al 2006, Ghiaur et al 2013). But the pathways utilized by either to mediate 
differentiation are still not clear.  
In this study, we investigated if HOXA5 in breast epithelial cells promotes 
transitioning of progenitor cells to a differentiated state. Our studies identified loss of 
expression of several typical epithelial specific genes and loss of the differentiation 
marker, CD24, occurred upon loss of HOXA5. We provide evidence that HOXA5 acts 
as a tumor suppressor gene through its ability to regulate cell adhesion through direct 
transcriptional upregulation of E-cadherin, and promotes lineage determination of stem 
cells through upregulation of CD24, two major characteristics typical of differentiated 
mammary epithelial cells. 
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2 Methods 
 
2.1 Cell lines and Reagents  
293T and MCF10A cells were obtained from the American Type Culture Collection, 
MCF10A-KRAS cells were generated by stably expressing mutant KRAS
G12V 
in 
MCF10A. SUM149 and SUM159 cells were obtained from Dr. S. Ethier (Wayne State 
University, Detroit, MI) and a lung metastatic subline of MDA-MB-231 cells called 
231-LM2 were obtained Dr. Joan Massagué. MCF10A was maintained in DMEM/F12 
supplemented with 5% horse serum, 20 ng/ml epidermal growth factor (#E9644), 500 
µg/ml hydrocortisone (#H0888), 10 µg/ml human recombinant insulin (#91077C) and 
100 ng/ml cholera toxin (#C8052) from Sigma. SUM149 and SUM159 were maintained 
in DMEM/F12 supplemented with 5% heat inactivated fetal bovine serum, 10 µg/ml 
insulin and 500 µg/ml hydrocortisone. 293T and 231-LM2 cells were maintained in 
DMEM/10% fetal bovine serum. All cells were maintained in medium containing 1000 
units/ml of penicillin/streptomycin. Stable cell lines were selected by puromycin 
(MCF10A – 1 µM) or hygromycin (SUM149 – 150 µM, SUM159 – 300 µM, 231-LM2 
– 700 µM, MCF10A – 100 µM) and the concentrations were empirically determined by 
killing curve assay. All resistant lines were pooled from surviving clones after 2-3 
weeks selection. All trans-retinal (#R2500) and all trans-retinoic acid (#R2625) were 
purchased from Sigma. 
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2.2 Plasmid constructs 
sh528 (TRCN0000017528) and sh529 (TRCN0000017529) were purchased from Open 
Biosystem. Tet-inducible shHOXA5 was generated by cloning targeting sequence from 
sh528 into pLKO-Tet-On plasmids purchased from Addgene. HOXA5 cDNA with 
myc-tag was cloned into pLHCX. Synonymous mutant (663bp to 683bp) was generated 
by site directed mutagenesis of HOXA5 for expressing sh529-resistant HOXA5 in 
MCF10A. For viral packaging, pLKO.1 vector (7 µg), pVSV-G (4 µg) and pCMV-
dR8.91 (4 µg) or pLHCX vector (7 µg) and pCL-Ampho (7 µg) were transfected in 
239T (10cm dish) for 36h and 72 hours prior to viral supernatant collection. Viral 
supernatant was filtered through 0.2 µm filter and 1ml of supernatant was used to infect 
cells in a 6-well plate. CDH1 and CD24 gene promoters were cloned into pGL2 
luciferase plasmid.  
2.3 Mammosphere formation assay 
Tumor sphere assays with the breast cancer cell lines were performed as previously 
described (Dontu et al 2003) with modifications. For low density assay, single cell 
suspension from 0.25 x 10
4
 of MCF10A-KRAS or 0.5 x 10
4
 of SUM149 were seeded in 
24-well ultra-low adhesion plates (Corning, #3473) in 1 ml of mammary epithelial 
growth media (MEGM, Lonza, #CC-3151), containing 1% methylcellulose (R&D 
Systems, #HSC001), to avoid aggregation and supplemented with 1X B27 (Invitrogen, 
#17504-44), 20 ng/mL EGF (Sigma, #E9644) and 20 ng/mL bFGF (Sigma, #F0291), 
and 4 μg/mL heparin (Sigma, #H1027). For secondary and tertiary sphere formation, 
spheres were dissociated into single cell at each passage by trypsinization (20 mins in 
0.25% trypsin-EDTA at 37
o
C and manually rock the tube few times) after growing for 
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14 days and then reseeded at 1x10
4
 cells/well. Quantification of the mammospheres was 
performed with ImageJ software.  
2.4 3D growth assay 
3D culture of the breast cancer cell lines was performed as previously described (Kenny 
et al 2007) with modifications. For MCF10A, 2 x 10
3
 cells were inoculated into 100 µl 
growth factor reduced Matrigel (#354230, BD), plated in 8-well chamber slide 
(#155411, Nunc) and maintained in 400 µl assay medium. For MCF10A-KRAS, 2 x 10
3
 
cells were inoculated into 100 µl of 50% Matrigel (#354234, Corning) and 50% 
Collagen I (1 mg/ml final concentration and gelatinized according to manufacturer’s 
protocol, #354236, Corning) mixture, plated in 8-well chamber slide and maintained in 
400 µl of MCF10A complete media. For 231-LM2, 2.5 x 10
3
 were inoculated into 100 
µl growth factor reduced Matrigel (#354230, BD) plated in 8-well chamber slide and 
maintained in 400 µl 231-LM2 complete medium. Cells were allowed to grow for 12-16 
days prior to imaging and enumerating colonies. Medium was replenished every 3-5 
days. 
2.5 Cell proliferation assay 
Cells proliferation assay was performed as previously described (Korangath et al 2015). 
Cells were plated in 96 well plates at 1500-3000 cells per well in 100 µl media. Number 
of cells was determined by MTT colorimetric assay. 100 µl of 0.5 mg/ml MTT solution 
was added to medium depleted well for 3 hours. 200 µl of DMSO was added to dissolve 
the formazan crystals. This solution was read at 570 nm absorbance in a microplate 
reader (BMG Labtech). 
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2.6 BrdU incorporation assay 
BrdU incorporation assay was performed according to manufacturer’s instructions with 
modification. Five thousands cells were seeded in 96 wells for 24 hours before the 
addition of BrdU. BrdU was added for 3 or 18 hours prior measurement.  
2.7 Wound healing assay 
Cells were grown to confluence in 6-well plate at the time of assay. The monolayer was 
scored with a p200 pipette tip to create a scratch. Media was replenished and the scratch 
was allowed to close up for 20-40 hours. Representative images were taken and the 
remaining clear area was quantified by ImageJ software.  
2.8 Cell Invasion assay 
1.5-5 x 10
4
 cells were seeded in 500 µl basal media in the Boyden chamber with 8 µm 
pores (#354480, BD) which was primed according to the manufacturer’s protocol. Cells 
were incubated in the chamber for 16-20 hours and the Matrigel barrier was gently but 
thoroughly removed with a cotton swab. The membrane was fixed with 10% formalin 
(#HT501128, Sigma) for 30 minutes and the cells were stained with 0.05% crystal 
violet and de-stained in tap water for imaging. Three chambers were used for each test 
and cell numbers were determined from 4 independent fields in each chamber.    
2.9 Quantitative RT–PCR  
Total RNA was extracted using TRIzol (Invitrogen) and treated with DNase I. Reverse 
transcription was performed with 1 ug of total RNA using oligo-dT and MMLV reverse 
transcriptase (Promega), according to the manufacturer’s instructions. Quantitative RT–
PCR was performed with SYBR Green dye using ABI 7500 Fast Real-Time instrument 
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(Applied Biosystem). Relative expression level of each gene was calculated by the 
relative CT value compared to that of the internal control ACTB gene. Gel based RT-
PCR was performed with optimal cycles and the PCR products were analyzed by 2% 
ethidium bromide agarose-gel. Primers (Sense, Anti-sense):  
HOXA5 (5’-CCCCAGATCTACCCCTGGATG, 5’-ACGAGAACAGGGCTTCTTCA), 
CDH1 (5’-CTGCTCTTGCTGTTTCTTCGG, 5’- TGCAGCTGGCTCAAGTCAAAG), 
CLDN1 (5’-CGATGCTTTCTGTGGCTAAAC, 5’-
CTGAGGGCATCACTGAACAGA),  
CD24 (5’-GGACATGGGCAGAGCAATGG, 5’-CCTTGGTGGTGGCATTAGTTG), 
DSG3 (5’-CAAAGAAGTTCAGCCACCCTC, 5’-CTCCTTGACTTCCTGACAAAG), 
ITGA10 (5’-CTAGGTGCCTGACTCCTTTC, 5’-GGAACAGGCAGGAAAGTGAG), 
FOXA1 (5’-CTCTTTCCCCTCCAGACATTC, 5’-CAGACCTGTAAACTCGTAGGG), 
FOXQ1 (5’-GCGGACTTTGCACTTTGAATCC, 5’-
CAAGAATTGCTTTGGTCCTCTG),  
CDH2 (5’-CCCACACCCTGGAGACATTG, 5’-GAGCCACTGCCTTCATAGTC), 
CDH3 (5’-CAGCCAACCCAGATGAAATCG, 5’-GCTGCCCTCATAGTCGAACAC), 
CLDN7 (5’-CAGGCTATGGGAGTGTCTAG, 5’-ACCCAAGAGGACTATACATGG), 
Occludin (5’-ATCAACTGGGCTGAACACTCC, 5’- 
GTATGAAGACATCGTCTGGGG), 
ACTB (5’- ATCAAGATCATTGCTCCTCCTG, 5’- CCTGCTTGCTGATCCACATC). 
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2.10 Western blot analysis 
Cells were lysed with RIPA buffer containing protease and phosphatase inhibitor and 
mixed by rotation at 4
o
C for 30 minutes. The lysates were centrifuged at 13,000 rpm for 
20 minutes. The supernatant was collected and quantified by BCA assay. 20-50 µg of 
protein were used to run on SDS-PAGE gel after being heated with sample buffer. The 
proteins were then transferred to nitrocellulose membranes. After being blocked in 5% 
milk for 1 hour, the membranes were blotted with primary antibody overnight and with 
secondary horseradish peroxidase-conjugated antibody for 1 hour. The membranes were 
developed using chemiluminescence (Amersham) with or without 10% of enhancer 
(#1856190). Western blotting was using these antibodies: HOXA5 (#sc-365784, Santa 
Cruz); E-cadherin (#13-1700, Invitrogen); Claudin-1 (#71-7800), Claudin-7 (#34-9100), 
Occludin (#71-1500), ZO-1 (#33-9100) and CK18 (#180158Z) were from Zymed; p21 
(Santa Cruz); β-actin (Sigma-A2228), cleaved caspase-3 (Cell Signaling).   
2.11 Immunohistochemistry 
IHC was performed as previously described (Korangath et al 2015) with modifications. 
Fresh xenograft tumors were fixed in 10% formalin and sectioned on positively charged 
slides. Vectastain ABC kit was used to perform IHC. After hydration with serial 
dilutions of ethanol, antigen retrieval was performed using 10 mM citrate buffer with 
0.05% Tween-20. The sections were then treated with 3% hydrogen peroxide for 10 
minutes and incubated with normal serum to block non-specific binding. The sections 
were then incubated overnight at room temperature with primary antibodies: HOXA5 
antibody (1:50, # sc-365784, Santa Cruz), E-cadherin antibody (1:500, #13-1700, 
Invitrogen), CK-18 (1:500, #180158Z, Zymed). Secondary antibody was added the next 
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day after washing, followed by incubation with ABC reagent and developed with the 
DAB reagent, and counterstained with hematoxylin as specified by manufacturer.  
2.12 Immunofluorescent staining and confocal microscopy 
For 2D images, cells were fixed with methanol (E-cadherin) or 4% paraformaldehyde 
(Phalloidin and Occludin) and stained with corresponding antibodies using the 
manufacturer’s protocol. Cells were treated with pre-extraction buffer prior to fixation 
for Occludin staining. Phalloidin-488 and secondary antibodies conjugated with Alexa-
fluor 488 (Invitrogen) were used. Confocal IF staining of 3D organoids was performed 
as described (Debnath et al 2003). IF staining was using these antibodies: E-cadherin 
(#13-1700, Invitrogen), Phalloidin-488 or Phallodin-568 (both from Invitrogen), 
cleaved caspase-3 (Cell Signaling). 
2.13 Fluorescence-Activated Cell Sorting and Quantification  
One x 10
6
 cells were stained on ice for 20 min with 5 µl of CD24-FITC (BD Pharmigen; 
clone ML5), 5 µl CD44-PE (BD Pharmigen; clone 515), 3 µl CD326 (EpCAM)-APC 
(Miltenyi Biotec, clone: HEA-125) and 5 µl of 7AAD (BD Pharmingen) to exclude 
dead cells, in 0.5% BSA/ 2mM EDTA/ PBS. Samples were run on the BD 
FACSCalibur system (Becton Dickinson), and data analyzed using FlowJo software. 
For apoptosis assay, 1 x 10
6
 cells were stained with 2.5 µl of Annexin V-Alexa 647 
(Life Technologies) and 5 µl of 7ADD. Cells were sorted on a BD FACSAria SORP 
and analyzed on a BDLSRII with BD FACSDiva Software (BD Biosciences). 
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2.14 Xenograft and Limiting Dilution Assay 
For the limiting dilution assay, breast cancer cells were digested with 0.05% Trypsin-
EDTA. Viable single cells were determined with Trypan blue exclusion and serially 
diluted to achieve 0.25 x 10
6
-0.25 x 10
3 
cells per injection. Cells were mixed with 
Matrigel and injected into mammary fat pads of immunocompromised NOD/SCID 
interleukin-2 receptor gamma chain null [Il2rg(-/-)], NOG mice. The fat pads were 
humanized by injecting a mixture of irradiated and non-irradiated (1:1) immortalized 
human fibroblast cells (25,000 cells/100μl Matrigel/fat pad) (Ginestier et al 2007, 
Kuperwasser et al 2004). Skin fibroblasts were provided by J. Campisi (Krtolica et al 
2001).  
2.15 Promoter Luciferase assay  
Confluent (90%) 239T cells in 12-well plate were co-transfected with 1µg amount of 
corresponding vectors, 50 ng of promoter luciferase constructs and 20 ng of β-
galactosidase plasmid using Lipofectamine 2000 (Invitrogen). The luciferase activity 
(#E1501, Promega) was measured 24 hours after transfection of cells and normalized to 
β-galactosidase activity (#117758241001, Roche).  
2.16 ChIP assay 
Methods described in (Jin et al 2012) were followed with modifications. Ninety percent 
confluent cells on a 10 cm dish was cross-linked with 1% formaldehyde and then 
quenched with 0.125 M glycine. Scraped and pelleted cells were lysed and sonicated 
using optimized conditions using a Bioruptor sonicator. Sonicated chromatin was 
enriched by using either 1 µg of α-myc or 3 µg of α-HOXA5 and same amount of IgG 
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isotype control and column-purified.  ChIP primers (Sense, Anti-sense) used for CDH1 
were (5’-AAAATTAGGCCGCTCGAGGC, 5’-GTATTTTTAGTACAGACGGGGT), 
and for CD24 were (5’-AGAGTGATGACGAATCTCCTC, 5’- 
CCCGTCATTCGTTTAAAGAGC). Distance sites primers used were: upstream CD24 
(5’- ATTGTAAGCATTGCTCCTCCC, 5’- GAGAAAGTGTGGTATAGAATGA), 
downstream CD24 (5’- TGCGAGGCAACCTTTCACGT, 5’- 
GTAGCGGCGACCCGAACAAA), upstream CDH1 (5’-
GGGACAGAATTCTCTGGAGAA, 5’-CAAAGCCAAAGACCAAAACCC), 
downstream CDH1 (5’- GAAGAGGAGGTTGAGGGCAC, 5’- 
CAAAGCCAAAGACCAAAACCC).  
2.17 Gene expression array and analysis 
RNA was extracted from MCF10A cells with RNeasy mini kit (#74104, Qiagen) 
according to manufacturer’s protocols. RNA was obtained from biological duplicate of 
each: MCF10A scramble, MCF10A-sh528 and MCF10A-sh529. RNA was hybridized 
onto Illumina’s HumanHT-12v4 BeadChip (Illumina, San Diego) using manufacturer 
recommended protocols. These chips provide comprehensive coverage of >47,000 
transcripts, including all current NCBI curated genes. After pre-processing using 
Illumina GenomeStudio software, quantile normalization was applied to log 
transformed intensities for future analyses. Statistical analyses were performed and 
figures of array data generated on the R statistical software using standard R tools, 
packages from the Bioconductor Bioinformatics Software Project, and customized 
programs when necessary.  
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2.18 Statistical Analysis  
Quantitative data were expressed as mean ± standard deviation (SD) of experimental 
triplicates or otherwise stated in the legends, and all statistical tests were analyzed by 
two-tailed student’s t test or otherwise stated, and considered statistically significant at 
p<0.05 [GraphPad Prism (v5.0, GraphPad Software, San Diego, CA)]. Tumor growth 
was presented as mean ± SEM and the statistical analysis performed using two tailed 
Student t test. Gene set enrichment analysis (GSEA) was performed with GSEA 
software on expression array data using default parameters on canonical pathway 
collections (Subramanian et al 2005). Statistical analysis and boxplot comparing 
HOXA5 expression across grade were generated from breast cancer data sets (Desmedt 
et al 2007, van 't Veer et al 2002) with R statistical software using standard R tools. 
Significance testing was performed using Welch’s corrected t-tests with Bonferroni 
correction for multiple testing. Relapse free survival curve using HOXA5 as a marker 
was performed with a web-based tool-Kaplan Meier plotter using median as the cut off 
(Gyorffy et al 2010). Tumor initiation frequency for the limiting dilution assay in vivo 
was determined by Poisson distribution evaluated by L-Calc software (with 95% 
confidence).  
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3 Results 
 
3.1 HOXA5 expression is frequently lost in breast cancer.  
Previous studies have provided evidence for loss of HOXA5 expression in 
breast cancer cell lines and in primary tumors (Coradini et al 2014, Henderson et al 
2006, Raman et al 2000). 
Analysis of TCGA dataset 
showed that HOXA5 level is 
significantly lower in breast 
cancer compared to normal 
breast tissue, regardless of 
breast cancer subtype (Figure 
3.1-1). MCF10A, a non-
transformed but 
immortalized mammary 
epithelial cell line, was used 
as a model to decipher the 
biological functions of 
HOXA5 in vitro. MCF10A, 
among  other immortalized 
Figure 3.1-1. HOXA5 expression level of 
different breast cancer sub-group in 
TCGA dataset. Pairwise comparisons of 
each group are statistically significant 
except the indicated pairs (NS= not 
significant).  
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breast cell lines, expressed a level of HOXA5 similar to primary human mammary 
epithelial cells (HMEC) while the majority of breast cancer cell lines express low or 
undetectable levels of endogenous HOXA5 (Figure 3.1-2).  
We confirmed the loss of HOXA5 protein in breast cancer by performing 
immunohistochemistry (IHC) on primary breast carcinomas. HOXA5 nuclear staining 
was detected in histologically normal mammary glands within the same section (Figure 
3.1-3A). We observed a progressive loss of HOXA5 from histological normal 
mammary gland to invasive ductal carcinoma lesions on the same section (Figure 3.1-
3B). Further, analysis of the expression profiles comparing micro-dissected cancer and 
normal lesions from same section   revealed that reduction in HOXA5 expression is 
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indeed epithelial specific (Figure 3.1-4). These findings using clinical samples indicate 
that the loss of HOXA5 may contribute to the progression of breast cancer.  
 
  
Figure 3.1-3. Immuno-histochemistry of breast cancer for HOXA5. A. Representative 
IHC images for HOXA5 of histological normal mammary glands (Normal) and invasive 
ductal carcinoma (Cancer). B. Representative IHC images for HOXA5 of histological 
normal mammary glands (Normal), ductal in situ carcinoma (DCIS) and invasive 
ductal carcinoma (Cancer). Arrows indicate nuclear staining of HOXA5.  
  
A 
B 
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Figure 3.1-4. HOXA5 expression in micro-dissected normal epithelium, normal stroma, 
tumor epithelium and tumor-associated stroma (left panel: epithelial compartment; 
right panel: stromal compartment.  
 
3.2 Depletion of HOXA5 perturbs epithelial characteristics. 
We depleted HOXA5 in MCF10A with a set of 5 shRNA and evaluated the 
expression of HOXA5 to determine the level of reduction. Two (sh528 and sh529) out 
of five shRNA were successful in substantially reducing the levels of HOXA5 protein 
(Figure 3.2-1A) and mRNA (Figure 3-2-1B). Further, as shown by q-RT-PCR, the level 
of depletion of HOXA5 in these sh-clones was more robust and consistent over several 
culture passages (Figure 3.2-1C).  
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Figure 3.2-1. Depletion of HOXA5 in MCF10A cells. A. Western blot analysis of 
endogenous HOXA5 in MCF10A cell lines stable express scramble shRNA, HOXA5 
targeting sh528, sh529, sh530, sh531 and sh532. B. RT-PCR analysis for HOXA5 
mRNA level of MCF10A cell lines stable express scramble, sh528 and sh529 shRNAs 
and C. HOXA5 targeting sh528, sh529, sh530, sh531 and sh532 over two time points of 
passage. In both assays, HOXA5 were substantially and robustly depleted with sh528 
and sh529 compared to scramble control.  
To gain further insight into pathways through which HOXA5 functions as a 
tumor suppressor gene, microarray analysis was performed with MCF10A cultures, 
MCF10A-sh528 and MCF10A-sh529, depleted of HOXA5 using two shRNAs (Figure 
3.2-1).  Pairwise differential expression analysis performed using Limma across 
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biological replicates identified 43 genes, including HOXA5 itself, that are differentially 
regulated with an FDR < 0.01 (Figure 3.2-2). The pipeline resulted in a subset of 
differentially expressed genes that were consistently and robustly altered across 
MCF10A-sh528 and MCF10A-529 compared to MCF10A-scr control. 
 
Figure 3.2-2. Hierarchical clustering heatmap showing genes differentially expressed 
between MCF10A-scr cells (n=2, biological duplicates) and HOXA5 depleted -sh528 
and -sh529 cells (n=2 each, biological duplicates) that have an FDR < 0.01.   
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We performed quantitative RT-PCR to validate a subset of highly differentially 
expressed genes identified by microarray analysis including CDH1, a cell adhesion 
protein; CD24, a differentiation marker; ALDH1A3, involved in retinal biosynthesis; 
CLDN1, a tight junction protein; ITGA10 and DSG3 (Figure 3.2-3A). To confirm the 
direct involvement of HOXA5 in the expression of these genes, HOXA5 was 
transfected back into these cells.  In both HOXA5-depleted cell cultures, ectopic 
expression of HOXA5 led to a substantial recovery of mRNA expression of each of the 
genes lost as a result of silencing HOXA5 (Figure 3.2-3A), suggesting that loss of gene 
expression was a direct consequence of HOXA5 loss. The data also showed that 
HOXA5 expression correlated with the expression of multiple genes that are necessary 
for the maintenance of epithelial cell identity in MCF10A.  
We also examined the expression level of several enzymes that are associated 
with retinoic acid biosynthesis in HOXA5-depleted MCF10A cells. The expression of 
AKR1C2 and AKR1B1 (members of aldo-keto reductase), as also of DHRS3, were 
decreased in HOXA5-depleted MCF10A cells. In contrast, proteins that have been 
implicated in enhanced cell invasion including ANPEP and MMP2 were elevated. An 
neuroendocrine secretory protein, CHGB, was also increased in HOXA5-depleted 
MCF10A cells. Ectopic expression of HOXA5 in the knock down cells, MCF10A-
sh528 and MCF10A-sh529 cells reversed the expression pattern of these genes (Figure 
3.2-3B).  
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Figure 3.2-3. Validation of the genes identified by micro-array analysis. A. Quantitative 
RT-PCR validation of a selection of five underexpressed (CDH1, CD24, ALDH1A3, 
CLDN1 and DSG3) and one overexpressed gene (ITGA10) identified in HOXA5-
shHOXA5 cells by the array.  
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Figure 3.2-3 B. Quantitative RT-PCR of genes discovered through microarray analysis 
that are involved in retinoic biosynthesis (AKR1C2, AKR1B1 and DHRS3) and cell 
invasion (ANPEP, MMP2 and CHGB). 
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One easily observable change that occurred in the phenotype of both MCF10A-
sh528 and MCF10A-sh529 cell lines was a loss of typical cuboidal epithelial 
morphology (Figure 3.2-4A), which was accompanied by a significantly increased 
capacity to invade through Matrigel barrier in Boyden chambers (Figure 3.2-4B) 
Conversely, ectopic expression of HOXA5 in aggressive SUM149, SUM159 and LM2 
[a lung metastatic derivative of MDA-MB-231 (Padua et al 2008)] breast cancer cells 
resulted in strikingly impeded invasiveness (Figure 3.2-4C-E). Furthermore, depletion 
of HOXA5 in breast cancer model MCF10A-KRAS cells also increased its invasiveness 
(Figure 3.2-4F).  
 
 
 
 
A. 
B. 
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Figure 3.2-4. Loss of HOXA5 increases cell invasiveness. A. Representative phase-
contrast images of MCF10A-scr and HOXA5 depleted -sh528 and -sh529 cells. 
Representative images and quantitative analysis of invaded cells in Boyden chamber 
and quantitative analysis of number of invaded cells in: B. MCF10A-scr and HOXA5 
depleted -sh528 and -sh529 cells. C. SUM149-vector and SUM149-HOXA5 cells. 
D.SUM159-vector and SUM159-HOXA5 (Quantitative analysis). E. MDA-MB-231-
LM2-vec, and MDA-MB-231-LM2-HOXA5 cells. F. MCF10A-KRAS-scr and 
MCF10A-KRAS–sh528 cells. Quantitation is presented in bar graphs.  
 
E. 
 
B 
F. 
 
B 
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Depletion of HOXA5 also altered the motility of MCF10A cells. In line with the 
observed traits, MCF10A-sh528 and –sh529 cells showed a two-fold higher efficiency 
in wound healing/migration capability compared to MCF10A-scr cells (Figure 3.2-5A), 
while the converse was evident in SUM149-HOXA5, SUM159-HOXA5 and LM2-
HOXA5 cells (Figure 3.2-5, B, D, E). Depletion of HOXA5 in MCF10A-KRAS model 
also slightly increased the motility of the cells (Figure 3.2-5C).  
 
 
A. 
  B. 
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Figure 3.2-5. HOXA5 impedes breast cancer cells motility. Representative images of 
wound healing assay and quantitative analysis of percent wound healing over different 
time course: A. MCF10A-scr and HOXA5 depleted -sh528 and -sh529 cells (24 hours). 
B. SUM149-vector and SUM149-HOXA5 cells (24 hours). C. SUM159-vector and 
C. 
D. 
E. 
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SUM159-HOXA5 cells (18 hours) D. MDA-MB-231-LM2-vec and MDA-MB-231-LM2-
HOXA5 cells (48 hours). E. MCF10A-KRAS-scr and MCF10A-KRAS–sh528 cells (18 
hours). Quantitation is presented in bar graphs.  
 
In four out of the five cells lines, the changes in cell invasion and cell motility 
were not dictated by altered cell proliferation, since no significant difference in cell 
proliferation was noted between controls and HOXA5-depleted or HOXA5-
overexpressing cells (Figure 3.2-6A-E). However, ectopic expression of HOXA5 
significantly reduced the growth of 231-LM2 cells. We further examined cell 
proliferation by performing BrdU incorporation assay. Similarly, no significant change 
in cell proliferation was observed between controls and HOXA5-depleted or HOXA5-
overexpressing cells (Figure 3.2-7A-E).  
All these pieces of evidence support the notion that HOXA5 expression 
influences the phenotype and behavior of the cell lines. In most cases, HOXA5 
expression status does not alter cell proliferation and growth. Together with the 
microarray analysis, the data is highly suggestive of the fact that HOXA5 regulates 
epithelial traits, which in turns maintain the typical characteristics of epithelial cells.  
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Figure 3.2-6. MTT growth analysis (n=5) 
over 72 (24 to 96) hours of A. MCF10A-scr 
and HOXA5 depleted -sh528 and -sh529 cells. 
B. SUM149-vector and SUM149-HOXA5 cells. 
C. SUM159-vector and SUM159-HOXA5 cells. 
D. MDA-MB-231-LM2-vec and MDA-MB-
231-LM2-HOXA5 cells. E. MCF10A-KRAS-
scr and MCF10A-KRAS–sh528 cells. 
 
 
 
A. B. 
C. D. 
E 
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Figure 3.2-7. BrdU incorporation analysis of A. 
MCF10A-scr and HOXA5 depleted -sh528 and -sh529 
cells (3 and 18 hours). B. SUM149-vector and 
SUM149-HOXA5 cells (3 and 18 hours). C. SUM159-
vector and SUM159-HOXA5 cells (3 and 16 hours). D. 
MDA-MB-231-LM2-vec and MDA-MB-231-LM2-
HOXA5 cells (3 and 18 hours). E. MCF10A-KRAS-scr 
and MCF10A-KRAS–sh528 cells (3 and 18 hours). 
 
  
D. 
A. B 
C. 
E. 
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3.3 Depletion of HOXA5 perturbs cell-cell adhesion.  
Some of the key molecular changes identified through our microarray analysis 
were those associated with epithelial traits of cell-cell adhesion and interaction. Gene 
set enrichment analysis (GSEA) of our microarray data revealed that MCF10A-scr cells 
were enriched for genes involved in cell-cell-adhesion and tight junctions (Figure 3.3-1).  
 
 
Figure 3.3-1. Gene set enrichment analysis of MCF10A-scr and HOXA5 depleted cells 
indicate that cell-cell junction genes are enriched in MCF10A-scr cells. Gene set 
enrichment analysis (GSEA) was performed with GSEA software on expression array 
data using default parameters on canonical pathway collections. (Class A: MCF10A-
scr, Class B: MCF10A-shHOXA5). 
 
The analysis corroborated our findings on the compromised epithelial traits 
observed in HOXA5-depleted MCF10A cells. Further, we examined a subset of genes 
that are associated with epithelial differentiation of mammary cells. Analyzing these 
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molecular changes associated with compromised epithelial integrity by RT-PCR, we 
observed loss of expression of E-cadherin (CDH1) was accompanied by an elevation of 
N-cadherin (CDH2) in HOXA5 depleted cells (Figure 3.3-2). Also evident was the 
decrease of expression of P-cadherin (CDH3) (Figure 3.3-2), which is known to disrupt 
the normal suppressor function of CDH1 by decreasing the interaction between CDH1 
and intracellular catenins (Ribeiro and Paredes 
2014). Occludin and claudin-7 (CLDN7), 
integral components of tight junctions in 
mammary epithelial cells, were also down-
regulated upon HOXA5 depletion (Figure 3.3-2). 
These molecular changes suggested that the loss 
of function in adhesion junction and tight 
junctions was associated with the phenotypic 
switch. Two other regulators of EMT, acting in 
opposing ways, were also investigated. There 
was loss of expression of the transcriptional 
factor FOXA1, a member of 
the forkhead class of DNA-binding proteins, 
which has been shown to potently neutralize 
several EMT-related, CDH1-repressed 
mechanisms (Wang et al 2013), while there 
was overexpression of another member of the 
same family, FOXQ1 (Figure 3.3-2), which 
Figure 3.3-2. RT-PCR analysis of 
differentiation markers in 
MCF10A-scr, HOXA5 depleted -
sh528 and -sh529 cells including 
EMT markers (CDH2 and CDH3), 
tight junction molecules (Occludin 
and CLDN7) and luminal fate 
markers (FOXA1 and FOXQ1).  
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represses CDH1 by binding to the E-box in its promoter region (Qiao et al 2011, Zhang 
et al 2011).  
As detected by Western blotting, the loss of epithelial traits in HOXA5-depleted 
MCF10A cells was accompanied by significant reduction in protein levels of CDH1, 
occludin, CLDN7 and CLDN1 (Figure 3.3-3).   
Furthermore, analysis of stable depletion of HOXA5 in MCF10A-sh528 and MCF10A-
sh529 cells markedly reduced CDH1 and CLDN1 expression, while re-expression of 
HOXA5 in these cells restored CDH1 and CLDN1 expression (Figure 3.3-4) and hence 
suggested a direct regulatory role of HOXA5 on CDH1 and CLDN1. HOXA5 thus 
Figure 3.3-3. Western blot analysis of 
differentiation markers in MCF10A-scr, 
HOXA5 depleted -sh528 and -sh529 cells 
including HOXA5 and HOXA5-regulated 
CDH1, Occludin, CLDN7 and CLDN1. β-actin 
serves as the loading  control.  
Figure 3.3-4. HOXA5 regulates CDH1 
and CLDN1 in MCF10A cells. Western 
blot analysis shows decrease in CDH1 
and CLDN1 protein upon HOXA5 
depletion in MCF10A cells; and 
reversal by ectopic expression of 
HOXA5 into the knock-down clones. β-
actin serves as the loading control. 
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appears to promote cell-cell adhesion and expression of epithelium-specific markers in 
breast cells.  
Immunofluorescence (IF) analysis provided additional evidence for membrane 
loss of CDH1 and Occludin, conferring an elongated morphology to the HOXA5-
depleted MCF10A cells (Figure 3.3-5A). The loss of membrane bound adhesion 
molecules upon the loss of HOXA5 in MCF10A cells was evident (Figure 3.3-5B). The 
analyses of the typical epithelial markers revealed the regulation of multiple 
components of adhesion and tight junctions by HOXA5, and thus strengthen the 
differentiation role in HOXA5.  
 
 
A. 
B. 
 
36 
 
 
Figure 3.3-5. HOXA5 regulates membrane-bound junctional proteins. A. 
Representative immunofluorescence images of CDH1 (Green), Occludin (Yellow), actin 
stress fiber, Phalloidin (Red) and nuclear marker, DAPI (Blue). B. Representative 
immunofluorescence images at 40X magnification of CDH1 (Green) and Occludin 
(Yellow).  
 
3.4 HOXA5 expression inhibits outgrowth of organoids in three 
dimensional (3D) cultures. 
 Transformed breast epithelial cells form protrusive and microinvasive structures 
in Matrigel, strongly associated with the epithelial-mesenchymal transitional state of the 
cells (Kenny et al 2007, Qiao et al 2011). Since depletion of HOXA5 resulted in the loss 
of epithelial properties in MCF10A, MCF10A-sh528 and MCF10A–sh529 cells were 
cultured in three-dimensional (3D) in Matrigel to assess their growth patterns.  
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Depletion of HOXA5 in MCF10A led to the formation of organoids of a more complex 
structure in Matrigel culture (Figure 3.4-1).  
 
Figure 3.4-1. Depletion of HOXA5 results in abnormal organoids formation. 
Representative phase-contrast images of MCF10A organoids formed in matrigel 3D 
culture.  
231-LM2 breast cancer cells express low or undetectable level of CD24 and 
Claudin-1. CD24 and Claudin-1 expression were restored when HOXA5 was 
ectopically expressed (Figure 3.4-3A). Since the proliferation of HOXA5 expressing 
LM2 cells was significantly reduced, we performed flow cytometry analysis using 
Annexin V and 7ADD staining to determine the apoptosis of the cells. 231-LM2-
HOXA5 cells exhibited an increased proportion of early apoptotic cells (Q4) and late 
apoptotic cells (Q3) (7.3% vs 10.6% and 4.5% vs 9% respectively, Figure 3.5-3C) 
although the increase was subtle. Nevertheless, cleaved caspase-3 was not detected in 
either 231-LM2-vector or –HOXA5 cells (Figure 3.4-3B), suggesting that cells did not 
undergo rigorous apoptosis in culture. In 3D assays in Matrigel, MDA-MB-231 lung 
metastatic derivative, 231-LM2-vec cells formed multiple branching and stellate 
structures in two weeks, while outgrowth of HOXA5 overexpressing 231-LM2-HOXA5 
cells was significantly inhibited (Figure 3.4-3A). Phalloidin staining of the organoids 
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corroborated the restricted growth phenotype in 231-LM2-HOXA5 cells (Figure 3.4-3B, 
quantified in 3.4-3C). We further performed cleaved caspase-3 staining in 3D culture to 
confirm the state of 231-LM2-HOXA5 cells in 3D culture. Cleaved caspase-3 staining 
was more prominent in the spheroid structure, which is the dominant structure in 
HOXA5 expressing 231-LM2 cells in matrigel. These structures also exhibited 
increased apoptotic blebs which is characterized by de-nucleated and GFP+ cytoplasm 
(Figure 3.4-3D).  
 
 
Figure 3.4-2. HOXA5 increases CD24 and CLDN1 but not cleaved caspase 3 in 231-
LM2 cells. Western blot analysis for A. CD24 and CLDN1 B. Cleaved caspase-3 in 231-
LM2-vector or 231-LM2-HOXA5cells. . β-actin serves as the loading control. C. Flow 
C. 
A. B. 
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B. 
A. 
C.
B. 
D.
B. 
cytometry analysis of Annexin V (x-axis) against 7ADD (y-axis) in 231-LM2-vector and 
231-LM2—HOXA5 cells. Quantitation is shown in the bar graphs. 
 
 
Figure 3.4-3. HOXA5 restricts organoids outgrowth and promotes apoptosis of 231-
LM2 cells in matrigel. Representative A. phase contrast and B. confocal images 
showing vector or ectopic HOXA5-expressing 231-LM2 organoids visualized with 
Phalloidin (Red) and DAPI (Blue). C. confocal images showing vector or ectopic 
HOXA5-expressing 231-LM2 organoids visualized with cleaved caspase-3 (Red), GFP 
(Green) and DAPI (Blue).  D. Quantitative analysis of spheroids or branched structures 
formed in Matrigel. 
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A.
B. 
D.
B. 
B
. 
C
B
. 
On the other hand, depletion of HOXA5 in MCF10A-Kras cells resulted in 
protruding outgrowths into a matrigel/collagen gel (Figure 3.4-4A-B) and this was 
accompanied by the loss of CDH1 expression (Figure 3.4-4C) and a significant increase 
in the number of branches (Figure 3.4-4D). Collectively, the data showed that 
expression of HOXA5 impedes protrusive and microinvasive outgrowth of organoids in 
3D cultures, and the increase in CD24 and Claudin 1 protein expression are supportive 
of HOXA5-mediated differentiation of breast cancer cells.  
 
 
Figure 3.4-4. HOXA5 prevents organoids outgrowth in MCF10A-Kras cells. 
Representative A. phase contrast, and confocal images of MCF10A-Kras-scr or 
HOXA5-depleted –sh528 organoids grown in Matrigel: Collagen I matrix and stained 
41 
 
with B. Phalloidin (Red), C. CDH1 (Green) and DAPI (Blue). D. Quantitative analysis 
of spheroids or branched structures of MCF10A-Kras cells formed in Matrigel/collagen. 
 
3.5 HOXA5 loss leads to an increase in stemness of epithelial cells. 
Human mammary epithelial cells have often been shown to acquire stem-like 
characteristics when they undergo EMT in vitro (Mani et al 2008, Radisky and LaBarge 
2008). Alterations typical of EMT, observed in our studies, raised the possibility of 
similar changes brought about by depletion of HOXA5 in MCF10A cells. Flow-
cytometry analysis of HOXA5-depleted MCF10A-sh528 and -sh-529 cells provided 
evidence for a reduction of the CD24
+
/CD44
+
 (from 65.8% to 20.2% and 42.9% 
respectively) population compared to MCF10A-scr cells (Figure 3.5-1A-B). There was 
an increase in the number of mammospheres formed by MCF10A-sh528 and –sh529 
cells (Figure 3.5-1C), suggesting that loss of HOXA5 skewed the MCF-10A cell 
population to a more progenitor-like state.  
 
 
 
A. 
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Figure 3.5-1. Depletion of HOXA5 enhances cell stemness in MCF10A. A. Flow 
cytometry analysis of CD24 (x-axis) against CD44 (y-axis) in MCF10A-scr, HOXA5 
depleted -sh528 and -sh529 cells. B. Quantitation is shown in the bar graphs. C. 
Representative images and quantitative analysis of mammosphere formation by 
MCF10-scr, HOXA5 depleted -sh528 and -sh529 cells. 
 
Our findings that loss of HOXA5 in MCF10A cells lead to increased migration, 
invasion, epithelial-mesenchymal transition, both in phenotypic and molecular 
characteristics, and acquisition of a more progenitor cell properties supported a role for 
HOXA5 as a differentiation factor in normal breast cells. This led us to investigate its 
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functions in MCF10A cells stably transformed by the K-ras oncogene. Depleting 
HOXA5 with shRNA in MCF10A-Kras significantly decreased the number of 
CD24
+
/CD44
lo
 cells (from 22.7% to 3%) (Figure 3.5-2A-B) and increased the number 
of mammospheres formed in culture (Figure 3.5-2C).  
 
 
 
Figure 3.5-2. HOXA5 inhibits cell stemness in MCF10A-Kras. A. Flow cytometry 
analysis of CD24 (x-axis) against CD44 (y-axis) in MCF10A-scr, HOXA5 depleted -
A 
B 
C 
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sh528 and -sh529 cells. B. Quantitation is shown in the bar graphs. C. Representative 
images and quantitative analysis of mammosphere formation by MCF10-scr, HOXA5 
depleted -sh528 and -sh529 cells. 
 
Conversely, in HOXA5 over-expressing SUM149 cells we observed an 
increased CD24
+
/CD44
+
 (from 47.9% to 75.1%) population (Figure 3.5-3A-B) and 
reduced mammosphere formation (Figure 3.5-3C) compared to SUM149-vector control. 
Over-expressing HOXA5 in SUM159 did not alter mammosphere formation; however 
CD24
+
/CD44
+
 population was elevated by 30% when analyzed by flow-cytometry 
compared to vector control (Figure 3.5-3D).  
 
 
A 
B 
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Figure 3.5-3. HOXA5 inhibits cell stemness in SUM149. A. Flow cytometry analysis of 
CD24 (x-axis) against CD44 (y-axis) in SUM149-vector and SUM149-HOXA5 cells. B. 
Quantitation is shown in the bar graphs. C. Representative images and quantitative 
analysis of mammosphere formation by SUM149-vector and SUM149-HOXA5 cells. D. 
Flow cytometry analysis of CD24 (x-axis) against CD44 (y-axis) in SUM159-vector and 
SUM159-HOXA5 cells. 
 
Our data suggested an inverse correlation between the expression of 
HOXA5/CD24 and mammosphere formation.  Therefore, we sought to determine if 
HOXA5 reduces self-renewal capacity in breast cancer cells. Serial passaging (Dontu et 
al 2003) was performed to determine the self-renewal ability of the MCF10A-Kras-scr 
and -sh528 cells. Depleting HOXA5 in MCF10A-Kras cells markedly enhanced 
C. 
D. 
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efficiency of mammosphere formation over the two passages (Figure 3.5-4A); in 
contrast, SUM149-HOXA5 cells formed few colonies in the first passage that could not 
be propagated further (Figure 3.5-4B).  
 
 
 
 
A. 
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Figure 3.5-4. Loss of HOXA5 promotes cell renewal capacity in breast cancer cells. 
Serial passage of mammospheres of:  A. MCF10-Kras-scr and HOXA5 depleted -sh528 
cells B. SUM-149-vector and -HOXA5 cells; each passage spans two weeks. 
Quantitative analysis of mammospheres formed in each passage is shown in the bar 
graphs. 
 
We further sorted breast cancer cell lines, MCF10A-KRAS and SUM149, with 
CD24 and CD44 cell surface markers and tested if CD24
-/lo
 population is capable of 
forming more mammospheres in vitro. As predicted, sorted CD24
+
/CD44
lo
 population 
Figure 3.5-5A) from MCF10A-KRAS cells formed significantly less number of 
mammospheres compared to the CD24
-
/CD44
hi
 counterpart (Figure 3.5-5B) and 
exhibited lesser self-renewal capacity in forming mammosphere on passage. On the 
other hand, CD24
-
/CD44
+
 population isolated from SUM149 formed significantly more 
B 
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mammospheres than CD24
+
/CD44
+
 population (Figure 3.5-5C). These findings suggest 
that expression of CD24 determines the intrinsic capability of mammosphere formation 
in breast cancer cell lines.  
 
 
 
A. 
B. 
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Figure 3.5-5. CD24-/lo identifies mammosphere forming cells in breast cancer. A. 
Flow cytometry cell sorting of CD24
+
/CD44
lo
 and CD24
-
/CD44
hi
 population from 
MCF10A-Kras cells or CD24
+
/CD44
+
 and CD24
-
/CD44
+
 populations from SUM149 
cells B. Serial passage of mammospheres of CD24
+
/CD44
lo
 and CD24
-
/CD44
hi
 cells 
isolated from MCF10A-Kras cells; each passage spans two weeks. Quantitative 
analysis of mammospheres formed in each passage is shown in the bar graphs. C. 
Representative image and quantitative analysis of mammosphere formation by 
CD24
+
/CD44
+
 and CD24
-
/CD44
+
 populations isolated from SUM149 cells. 
 
Supporting these observations, CD24 and CDH1 mRNA expression was lost in 
MCF10A-Kras-sh528 cells (Figure 3.5-6A). CDH1 protein was undetectable in 
HOXA5-silenced, MCF10A-Kras-sh528 cells. Conversely, CDH1 protein levels 
increased by 2-fold in SUM149-HOXA5 cells (Figure 3.5-6B). Collectively, these 
findings strongly suggested that HOXA5 is functionally necessary, but not sufficient, to 
reverse stemness in breast cancer cells.   
 
C. 
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Figure 3.5-6. HOXA5 expression is associated with CDH1 and CD24 expression in 
MCF10A-Kras and SUM149 cells. A. Quantitative RT-PCR of HOXA5, CDH1 and 
CD24 expression level in MCF10A-Kras-scr and MCF10A-Kras-sh528 cells. B. 
Western Blot analysis of HOXA5 and CDH1 protein in MCF10A-Kras-scr, -sh528, 
SUM149-vec and -HOXA5 cells. β-actin serves as the loading control. 
A. 
B. 
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3.6 HOXA5 delays tumor initiation and controls tumor 
differentiation. 
Isolated CD24
-/low
/CD44
+
 population from breast cancer cells or solid tumors 
has been reported to contain tumor-initiating or cancer stem cells that are more 
tumorigenic than their counterparts in vivo. Since ectopic expression of HOXA5 leads 
to increase in CD24
+
 population in SUM149 cells, we evaluated the stemness of 
SUM149 tumor cells in vivo by performing limiting dilution transplantation 
experiments using orthotopically injected xenografts. Serially diluted SUM149-HOXA5 
cells were injected into humanized mammary fat pads (hmfp) (schema in Figure 3.6-
1A). The frequency of palpable tumors was first assessed at the beginning of the fourth-
week. A nearly 17-fold reduction in the frequency of stem cells (Figure 3.6-1B) and 
reduction in tumor volume (Figure 3.6-1C) was observed in the SUM149-HOXA5 cells 
compared to SUM149-vec control cells. These in vivo findings confirmed our 
observations in the mammosphere formation assay of SUM149 in culture that HOXA5 
has the capacity to induce differentiation, thereby possibly reducing the number of stem 
cells in the tumorigenic xenograft. 
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Figure 3.6-1. HOXA5 delays tumor initiation and tumor growth of SUM149 cells in 
mice. A. Sites of orthotopic injection of serially diluted SUM149 cells in the 4
th
 and 5
th
 
mammary fat pads of NOG mice. B. Table shows xenograft incidence at 3 weeks after 
orthotopic injection of SUM149-vector or SUM149-HOXA5 cells (n=7 mice for each 
dilution). Stem cell frequency was evaluated by L-Calc software (with 95% confidence). 
C. Tumor growth of SUM149 vector vs HOXA5 xenografts following injection of 2.5 x 
10
4
 cells (n=7 mice). Tumor volumes at each time point are means with SEM, and 
statistical differences in tumor volumes was analyzed by performing two-tailed 
student’s t test. 
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We confirmed these findings in an additional model system. In contrast to 
HOXA5 over-expressing SUM149 cells, HOXA5 depleted MCF10A-Kras-sh528 
xenografts appeared significantly earlier and grew more rapidly than vector control cells 
(Figure 3.6-2).   
 
Histopathology of the tumors showed a well differentiated histopathology, 
characterized by the formation of pseudo-ductal structure with stronger counterstaining 
with eosin (Figure 3.6-3, left panels, low and high magnification). MCF10A-Kras-
sh528 tumors, on the other hand, failed to form duct-like structures and tumor cells 
exhibited a mesenchymal and dedifferentiated morphology (Figure 3.6-3, right panels).  
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Figure 3.6-2. Loss of HOXA5 promotes tumor growth of MCF10A-Kras cells in vivo. 
A. Tumor growth of MCF10A-KRAS-scr vs -sh528 xenografts over 7 weeks following 
injection of 2.5 x 10
4
 explanted cells (n=9 mice). Tumor volumes at each time point are 
means with SEM, and statistical differences in tumor volumes was analyzed by 
performing two-tailed student’s t test. 
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Figure 3.6-3. Loss of HOXA5 results in dedifferentiation of MCF10A-Kras in vivo.  
Representative H/E stained histology images of MCF10A-KRAS-scr and HOXA5-
depleted MCF10A-KRAS-sh528 xenografts. Quantitative analysis of pseudo-ductal 
structure formed in MCF10A-KRAS-scr and HOXA5-depleted MCF10A-KRAS-sh528 
xenografts.  
 
Further characterization of the xenografts by IHC showed positive nuclear 
staining for HOXA5, adhesion junction staining for CDH1 and cytoplasmic staining for 
CK18 in cells surrounding the pseudo-glandular structures in MCF10A-Kras xenografts 
while immunostaining was negative for these markers in MCF10A-Kras-sh528 tumors 
(Figure 3.6-4). The morphology of the cells and loss of luminal epithelial markers 
provided further evidence that the loss of HOXA5 resulted in the formation of more 
aggressive and dedifferentiated tumors in vivo.  
A. B. 
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Figure 3.6-4. IHC characterization of MCF10A-Kras xenografts. Representative 
images are shown of IHC for HOXA5, CDH1 and CD18 in MCF10A-KRAS-scr and -
sh528 tumors. Note nuclear staining for HOXA5, and cell surface staining for CDH1 
and cytokeratin, CD18. 
 
 These findings led us to examine the correlations between HOXA5 and the 
clinical factors in breast cancer. Meta-analysis revealed an inverse correlation between 
HOXA5 and grade of breast cancer in both the publicly available NKI and Desmedt 
data sets (Figure 3.6-5A and B). Furthermore, KM-Plot analysis also showed that 
HOXA5 expression correlated with better relapse free outcome in breast cancer patient 
(Figure 3.6-4).   
            
 
 
 
scr
sh528
α-HOXA5 α-CDH1 α-CK18
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Figure 3.6-5. HOXA5 inversely correlates with pathological grades of breast cancer. 
In silico analysis of correlation between HOXA5 transcript level and pathological 
grades of primary breast tumors from: A. NKI and B. Desmedt datasets. 
B A 
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Figure 3.6-6. HOXA5 predicts better prognosis in breast cancer patients. Relapse free 
survival curve of HOXA5 was derived with a web-based tool-Kaplan Meier plotter 
using median as the cut off (High>median, Low<median). 
 
 
 
 
 
 
 
Relapse free survival analysis of HOXA5
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3.7 Differentiation of the CD24
-
/CD44
+
 population by retinal is 
partially mediated by HOXA5.    
Our findings clearly highlight HOXA5’s function in suppressing EMT 
characteristics, but a possible dynamic role for HOXA5 during cell fate transition is yet 
to be addressed. Pathway analysis of the differentially expressed genes in HOXA5-
depleted MCF10A cells revealed changes in genes involved in retinoic acid 
biosynthesis, such as ALDH1A3 and DHRS3. Retinoic acid signaling and HOX genes 
have long been implicated in tissue differentiation and development (Strickland and 
Mahdavi 1978, Wang et al 2005). Moreover, previous publications from others and us 
have provided evidence that retinoic acid receptors are direct transcriptional regulators 
of HOXA5 (Chen et al 2007). We developed an inducible HOXA5 knockdown model 
in MCF10A cells that would allow us to study the dynamics of this transition. 
Doxycycline-induced loss of HOXA5 in MCF10A-tet-sh528 resulted in a sequential 
loss of CDH1 protein level and CD24
+
 population over time (Figure 3.7-1A and B) and 
loss of expression of CD24 and CDH1 mRNA, an effect not observed in MCF10A-vec 
cells treated with doxycycline (Figure 3.7-1D). As seen in Figure 3.7-1A  and in the 
Western blot in Figure 3.7-1B, reduction of HOXA5 expression was observed as early 
as 24h, followed by reduction in CDH1 and CD24 protein levels. CD24
- 
population in 
MCF10A-tet-sh528 cells was isolated by flow-cytometry cell sorting, and the cells were 
cultured for one week in vitro. Cells were treated with retinal to induced differentiation 
with or without the addition of doxycycline to study the functions of HOXA5 in the 
differentiation cascade (schema Figure 3.7-1A-C). 
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Figure 3.7-1. CDH1 and CD24 are early downstream targets of HOXA5 in MCF10A 
cells. A. Western blot analysis of HOXA5 and CDH1 expression in MCF10A-tet-sh528 
cells with dox-induced depletion of HOXA5 over 96 hours. β-actin serves as the loading 
control.  B. Flow cytometry analysis of CD24 expression in MCF10A-tet-HOXA5 with 
doxycycline-induced depletion of HOXA5 over 96 hours. Quantitative analyses of 
CD24
+
/CD44
+
 and CD24
-
/CD44
+
 populations is shown in the bar graph. C. Flow 
sorted CD24
-
 population was treated with DMSO, 1 µM retinal (ATAL) or 1 µM ATAL 
+ 100 nM doxycycline (DOX) and cultured for 1 week. D. Quantitative RT-PCR 
analysis of HOXA5, CDH1 and CD24 expression over 120 hours doxycycline treatment 
in MCF10A-tet-vector and MCF10A-tet-sh528 cells. 
Compared to the number of CD24
+/
CD44
+ 
cells in DMSO-treated cells, 
treatment with retinal (1uM) resulted in a striking enrichment (40% to 96%) of this 
population. Concurrent repression of HOXA5 with doxycycline along with the HOXA5 
inducer, retinal, resulted in partial abrogation of retinal-mediated increase in 
CD24
+/
CD44
+ 
population (96% to 70%)(Figure 3.7-2A). Bar graphs show quantitation 
of CD24
+/
CD44
+
, and of CD24
-
/CD44
+
 populations (Figure 3.7-2B). 
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mRNA expression of CD24, CDH1, Occludin and CLDN7, but not ALDH1A3 
was induced by retinal, and all the genes were repressed when HOXA5 was 
simultaneously silenced in MCF10A (3.7-3A). Differentiation induced by retinal is 
further characterized by the elevation of junctional and structural proteins which 
expression is epithelial specific. Western blot analysis of CDH1, ZO-1, Occludin, 
CLDN7, CK18 and cell cycle arrest protein, p21, showed elevated expression upon 
retinal treatment which was reversed by depleting HOXA5 (Figure 3.7-3B). Taken 
together, we concluded that retinal-induced cell differentiation in MCF10A cells is, in 
part, driven by HOXA5. Further substantiation was sought through additional assays of 
stem cell differentiation in MCF10A-tet-sh528 cells. Retinal inhibited mammosphere 
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Figure 3.7-2. HOXA5 mediates 
upregulation of CD24 in MCF10A cells 
by retinal. A. Flow cytometry analysis of 
CD24 (x-axis) and CD44 (y-axis) in the 
cells treated as shown in (3.7-1C). B. 
Quantitative analyses of CD24
+
/CD44
+
 
and CD24
-
/CD44
+
 populations is shown 
in the bar graph 
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formation while concurrent knockdown of HOXA5 in the presence of retinal 
significantly restored the ability of the cells to form mammospheres (3.7-3C). These 
findings strongly suggested that HOXA5 is one of the key mediators of retinal-induced 
differentiation in MCF10A cells.  
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Figure 3.7-3. HOXA5 mediates differentiation of MCF10A cells by retinal. A. 
Quantitative RT-PCR analysis of HOXA5, CD24, CDH1, Occludin, CLDN7 and 
ALDH1A3 in MCF10A-te-sh528 cells treated as indicated in (3.7-1C) B. Western blot 
analysis of HOXA5, CDH1, p21, ZO-1, Occludin, CLDN7 and CK18 in the cells treated 
as shown in (3.7-1C). β-actin serves as the loading control. C. Representative images 
and quantitative analysis of mammosphere formation in MCF10A-tet-sh528 cells 
treated with DMSO, ATAL, ATAL + DOX for one week. 
 
3.8 HOXA5 is a direct transcriptional regulator of CDH1 and CD24.   
How does HOXA5 regulate the multiple traits typical of luminal epithelial cells 
in the mammary gland? We addressed this question for CDH1 and CD24 which showed 
strong correlation with HOXA5 expression. We performed promoter-linked luciferase 
assays for CDH1 and CD24 to investigate whether expression of HOXA5 trans-activate 
the promoters of CDH1 and CD24. Transient expression of HOXA5 along with the 
luciferase constructs in 293T cells resulted in a significant induction of luciferase 
activity driven by the promoters of both CDH1 (Figure 3.8-1A) and CD24 (Figure 3.7-
1B).  The homeodomain was necessary for this activity in both promoters, since 
C. 
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luciferase activity was significantly abrogated when 293T cells were transfected with 
HOXA5 (Del HD) instead of wild type HOXA5 (Figure 3.8-1A and 3.8-1B).  
 
 
Figure 3.8-1. HOXA5 increases promoter-luciferase activity of CDH1 and CD24. 
Promoter linked luciferase activity was analyzed in 293T cells, 24 h after cotransfection 
of A. a luciferase construct containing the promoter sequence (-1000 bp) of E-cadherin 
or vector control, or B. a luciferase construct containing the CD24 promoter (-1100 bp 
to +150bp) and vector control, each with wild type (WT) or homeodomain truncated 
      E-cadherin promoter-Luciferase
0 5 10 15 20 25
Del HD
WT
Vector
***
***
Fold difference (Luciferase/-gal)
-1000 0
Luc
       CD24 promoter-Luciferase
0 5 10 15 20
Del HD
WT
Vector
***
***
Fold difference (Luciferase/-gal)
-1100 Luc+150B. 
A. 
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(ΔHD) HOXA5, and β-galactosidase plasmid to control for transfection efficiency 
shows that HOXA5 upregulated luciferase activity of both promoters, which was 
significantly attenuated when the HD was truncated. 
 
We further performed ChIP assays on MCF10A cells overexpressing HOXA5 
(myc-tag) to determine the occupancy of HOXA5 at a putative HOX-binding-site 
(TAAT) located in each of the gene promoters. In both cases, we observed statistically 
significant enrichment of HOXA5 at their respective sites in chromatin, compared to the 
vector controls, confirming HOXA5 occupancy at the region. In parallel, no significant 
ChIP enrichment by HOXA5 was detected at two distanced sites which are 
approximately 2000bp upstream or downstream of these regions of promoters of CDH1 
or CD24 (Figure 3.8-2A and 3.8-2B). In sum, these results suggested that HOXA5 is a 
transcriptional regulator of two luminal-specific genes, CDH1 and CD24. Next, we 
sought confirmation in cells with induced expression of the endogenous HOXA5 gene 
to determine if HOXA5 induced by retinal treatment in MCF10A cells could bind to the 
CD24 promoter. ChIP analysis showed that HOXA5, induced by retinal, bound to the 
promoter region of CD24 in MCF10A cells. Moreover, when HOXA5 was depleted by 
addition of doxycycline, its occupancy at the same region was significantly reduced. 
The enrichment, however, was not detected at the distant regions which are 
approximately 2000 bp upstream or downstream from this site (Figure 3.8-2C). This 
finding strengthens the transcriptional role of HOXA5 in retinal mediated induction of 
CD24 expression.  
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Figure 3.8-2. HOXA5 occupancy at the promoters of CDH1 and CD24. A. ChIP 
analysis of the E-cadherin promoter was performed in vector or myc-tagged-HOXA5 
expressing MCF10A-sh528 cells using α-myc antibody and isotype IgG control. PCR 
shows enrichment of occupancy of HOXA5 at the -1003 bp to -859 bp region of E-
cadherin containing putative TAAT HOX-binding site upstream of its transcription start 
site but not at the upstream (-2426 bp to -2421 bp) and downstream (+1333 to +1443) 
regions. There was no enrichment in the IgG ChIP. B. ChIP analysis of CD24 promoter 
was performed in vector or myc-tagged HOXA5 expressing MCF10A-sh528 cells using 
α-myc antibody and isotype IgG control. Bar graph showing enrichment of occupancy 
of HOXA5 at the -1128 bp to -1016 bp region of CD24, containing a putative TAAT 
HOX- binding site upstream of CD24 transcription start site but not at the upstream (-
3470 bp to -3300 bp) and downstream (+785 to +926) regions. There was no 
enrichment in the IgG ChIP. C. ChIP analysis of CD24 promoter in DMSO, ATAL or 
ATAL+DOX treated MCF10A cells using α-HOXA5 antibody or isotype IgG control. 
Bar graph shows enrichment of occupancy of HOXA5, but not when HOXA5 was 
depleted, at the -1128bp to -1016bp region of CD24 promoter. There was no 
-3470 to -3300 -1128 to -1016
TSS
0 +785 to +926
-3470 to -3300 -1128 to -1016 +785 to +926
C. 
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enrichment at the upstream (-3470 bp to -3300 bp) and downstream (+785 to +926) 
region.  
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4 Discussion 
 
Our investigation has revealed a role for HOXA5 in regulating cell 
differentiation, cell specification and tumor initiation in breast cancer, and provided 
mechanistic insight into how HOXA5 maintains homeostasis in mammary epithelial 
cells. Microarray analysis of human mammary epithelial cells identified E-cadherin 
(CDH1) and CD24 as key molecules whose expression is lost as a consequence of loss 
of HOXA5. We present evidence that HOXA5 is a direct transcriptional regulator of 
both CDH1 and CD24. Further, HOXA5 loss leads to reduced CDH1 expression and 
subsequent development of hallmarks of epithelial mesenchymal transition, invasion 
and migration, while reduced CD24 expression and consequent enrichment of CD24
-
/CD44
+
 population leads to an expansion of breast cancer stem cells and rapid tumor 
growth.  
 Depletion of HOXA5 in MCF10A cells resulted in acquisition of cell motility, 
and invasiveness and an ability to form mammospheres, suggestive of a tumor 
suppressive role for HOXA5 in cancer progression. Loss of (CDH1), tight junction 
protein (CLDN1), desmosome proteins (DSG3) and luminal fate marker, CD24 and 
down-regulation of retinoic acid metabolic enzymes, ALDH1A3 and DHRS3 were all, 
collectively, indicators of the disruption of differentiation signals. The findings that 
HOXA5 depletion results in loss of structural proteins of the cells are in agreement with 
the findings that HOXA5 can transcriptionally regulate multiple members of the actin 
cytoskeleton in non-small cell lung carcinomas (Wang et al 2015) and can impede cell 
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migration and invasion in culture (Korangath et al 2015, Wang et al 2015). Our findings 
uncover a possible link between HOXA5 and epithelial integrity, which when disrupted, 
leads to the cancer development.  
Although members of HOX5 genes have been implicated in cellular 
differentiation, most of the evidence was gathered from non-mammalian models 
(Henderson and Andrew 2000). The size of HOXA5 null mice was found to be smaller 
than heterozygous littermates, and many died within a week of birth due to respiratory 
tract defects (Aubin et al 1997). Survivors showed delayed and abnormal mammary 
development during pregnancy, leading to production of very little or no milk, but did 
not develop mammary tumors. In the mouse, the investigators showed that HOXA5 loss 
in the stroma, not the epithelium, was responsible for abnormalities in development of 
the mammary gland (Garin et al 2006). In recently developed HOXA5-cre models 
(Berube-Simard and Jeannotte 2014), skeletal and other abnormalities were detected, 
but no mammary tumors were reported, indicating that loss of HOXA5 alone is 
insufficient for tumorigenesis. Technical limitations have hindered the exploration of 
the mechanism of regulation of mammary cell differentiation by HOXA5. Our studies 
were facilitated by generating MCF10A mammary epithelial cells with Tet-inducible 
shHOXA5. Using these cells and other models, our data is supportive of a role for 
HOXA5 in specifying cell fate brought about by up-regulating critical cell surface 
proteins that maintain the structural integrity of epithelial cells. Our studies, using 
promoter-linked luciferase assays and ChIP analysis showed that the expression of 
CDH1 is transcriptionally regulated by HOXA5 in MCF10A cells. Expression of 
occludin and claudins was also reduced in cells stably depleted of HOXA5. Like 
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occludin, CLDN1 and CLDN7 are important components of tight junctions, a barrier 
expressed primarily in differentiating ductal cells. However, their expression is 
consistently lost in many breast carcinomas and breast cancer cell lines (Kominsky et al 
2003, Kramer et al 2000, Martin et al 2010, Swisshelm et al 1999, Tokes et al 2005). 
Hence, these findings provide evidence for yet another of the many complex functions 
of HOXA5- that of regulating structural integrity of epithelial cells and thereby, likely, 
cellular patterning and development.  
We show that silencing of HOXA5 in MCF10A cells leads to the reduction in 
expression of CD24. Based on the loss of a differentiated cell marker CD24, we 
predicted that HOXA5 depleted MCF10A will convert to more primitive and basal 
phenotypes. Using a combination of knockdown of HOXA5 in MCF10A-Kras, and 
overexpression in SUM149 or SUM159 breast cancer cell lines, we have shown that 
HOXA5 reduces CSC population defined by expression of CD24/CD44 markers. 
Increase of the more differentiated CD24
+
 population, reduction of self-renewal 
capacity accompanied by elevation of CDH1 expression provides strong evidence that 
HOXA5 impedes stemness of breast cancer cells. Our results support the theory that 
breast cancer cells might acquire enhanced ability to form tumors when they regress to a 
more undifferentiated state (Keller et al 2010). In fact, tumor initiating cells were 
generated through dedifferentiation of epithelial cells in a murine intestinal model 
(Schwitalla et al 2013). Our results support several tenets of this reversion theory: 1) 
Expression of HOXA5 markedly reduced the number of tumor initiating cells in 
limiting dilution assays performed in immunodeficient mice. Also, depletion of HOXA5 
in MCF10A-Kras cell line resulted in the formation of histopathologically 
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dedifferentiated xenografts, an observation that is in agreement with the inverse 
correlation between HOXA5 expression and pathological grades of breast cancer and 
poorer survival outcomes. These observations strongly support a differentiating role for 
HOXA5, which may limit tumor initiating capacity in breast cancer.   
It remains unclear what drives the transition from a primitive to the 
differentiated axis. The inducible HOXA5 knock down model system in MCF10A cells 
allowed us demonstrate the role HOXA5 in retinal-mediated transition from the CD24- 
to CD24+ axis, which was characterized by elevated expression of epithelial specific 
CDH1 and several tight junction proteins. Retinal significantly increased the CD24
+
 
population through upregulation of HOXA5 in MCF10A, consequently decreasing their 
mammosphere-initiating capability. Our findings are consistent with the presumed role 
of retinoic acid pathway in cellular differentiation (Chute et al 2006, Ghiaur et al 2013, 
Strickland and Mahdavi 1978) . We further confirmed that HOXA5 is necessary, but 
not sufficient for the differentiation process. Although cell surface molecules are useful 
for delineating specific cell lineage, there are not many studies focusing on 
transcriptional cues for cell state transition. As a regulator of differentiation of the 
epithelial lineage, we have shown that HOXA5 transcriptionally regulates CDH1 and 
CD24 through promoter binding. Thus, our findings identify novel molecular pathways 
to evaluate molecular perturbation during the transition of cell fate in vitro.  
This study strongly supports a role for HOXA5-mediated differentiation in 
mammary ductal development. Our microarray data support the fact that HOXA5 may 
control tumor environment through regulation of extracellular matrix components, 
which can contribute to the forming of the differentiated structures. Studies in the future, 
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could address developmental mechanisms driven by HOXA5 in the presence of 
environmental cues.  
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Appendix 
 
 
  
Genes differentially expressed between MCF10A-scr and HOXA5 depleted cells that have an FDR < 0.05. 
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Genes differentially expressed between MCF10A-scr and HOXA5 depleted cells that have an FDR < 0.05. 
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Genes differentially expressed between MCF10A-scr and HOXA5 depleted cells that have an FDR < 0.05. 
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Genes differentially expressed between MCF10A-scr and HOXA5 depleted cells that have an FDR < 0.05. 
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